Protagen AG, a specialist for GMPcompliant protein analysis and in-vitro diagnostics is participating at the European Antibody Congress in Geneva. The experts of the company will present the characterization of biotherapeutics - monoclonal antibodies and biosimilars - with protein microarrays and the latest developments of GMPcompliant protein analysis.
The protein microarrays of the UNIchip® product family allow faster and more efficient selection of therapeutic antibodies and high affinity biotherapeutic reagents with improved specifity and stability already in the development phase. The special design of the UNIchip® products enables the qualitative and quantitative measurement of unspecific binding events of biotherapeuticals, so called "off-target activities". This allows to predict the performance in pharmacokinetic testing and guides the selection of the most promising candidates for further development. The UNIchip® technology is also applied to optimize downstream processing and stability testing of antibodies.
The service and method portfolio platforms established at Protagen AG range from GMP-compliant characterization of biotherapeuticals to biological potency assays. The combination of high resolution tests for structural analysis with optimized methods for biological activity results in a comprehensive product characterization.
You are cordially invited to meet us at the European Antibody Congress exhibition forum and join the presentation of Dr. Schulz-Knappe, CSO, on November 29th, 12.05 pm, entitled "Characterization of therapeutic antibody candidates by protein microarrays". For further information please refer to http://www.terrapinn.com/....
The protein microarrays of the UNIchip® product family allow faster and more efficient selection of therapeutic antibodies and high affinity biotherapeutic reagents with improved specifity and stability already in the development phase. The special design of the UNIchip® products enables the qualitative and quantitative measurement of unspecific binding events of biotherapeuticals, so called "off-target activities". This allows to predict the performance in pharmacokinetic testing and guides the selection of the most promising candidates for further development. The UNIchip® technology is also applied to optimize downstream processing and stability testing of antibodies.
The service and method portfolio platforms established at Protagen AG range from GMP-compliant characterization of biotherapeuticals to biological potency assays. The combination of high resolution tests for structural analysis with optimized methods for biological activity results in a comprehensive product characterization.
You are cordially invited to meet us at the European Antibody Congress exhibition forum and join the presentation of Dr. Schulz-Knappe, CSO, on November 29th, 12.05 pm, entitled "Characterization of therapeutic antibody candidates by protein microarrays". For further information please refer to http://www.terrapinn.com/....
